BMO Capital analyst, Gary Nachman, reiterated his Outperform rating on shares of Sage Therapeutics (NASDAQ: SAGE) after the company provided ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE